QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease

Bibliography

• COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994;105:1411-19
   PubMed Web of Science ®Google Scholar
• National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. National Clinical Guideline Centre, London; 2010. Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/English [Last accessed June 2010]
   Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-91
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD 2014. Available from: www.goldcopd.org
   Google Scholar
• Cazzola M, Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010;23:257-67
   PubMed Web of Science ®Google Scholar
• Meurs H, Oenema TA, Kistemaker LE, et al. A new perspective on muscarinic receptor antagonism in obstructive airways diseases. Curr Opin Pharmacol 2013;13:316-23
   PubMed Web of Science ®Google Scholar
• van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012;21:101-8
   PubMedGoogle Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64:450-504
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Bronchodilators: current and future. Clin Chest Med 2014;35:191-201
   PubMed Web of Science ®Google Scholar
• Mahler DA, D’Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012;67:781-8
   PubMed Web of Science ®Google Scholar
• Vincken W, Aumann J, Chen H, et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis 2014;9:215-28
   PubMed Web of Science ®Google Scholar
• Cazzola M, Bardaro F, Stirpe E. The role of indacaterol for chronic obstructive pulmonary disease (COPD). J Thorac Dis 2013;5:559-66
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Cazzola M. Indacaterol for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2015;16:107-15
   PubMed Web of Science ®Google Scholar
• Charlton SJ. Agonist efficacy and receptor desensitization: from partial truths to a fuller picture. Br J Pharmacol 2009;158:165-8
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther 2013;26:307-17
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2014;15:961-77
   PubMed Web of Science ®Google Scholar
• Anonymous. Novartis announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to US FDA. Available from: http://www.novartis.com/newsroom/media-releases/en/2015/1885149.shtml [Last accessed 8 January 2015]
   Google Scholar
• Kume H, Imbe S, Iwanaga T, et al. Involvement of the BK channels/G proteins processes in the synergistic effects between anticholinergic agents and beta2-adrenoceptor agonists in airway smooth muscle [abstract]. Eur Respir J 2013;42(Suppl 57):3032
   Google Scholar
• Cazzola M, Calzetta L, Segreti A, et al. Translational study searching for synergy between glycopyrronium and indacaterol. COPD 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Frampton JE. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs 2014;74:465-88
   PubMed Web of Science ®Google Scholar
• van Noord JA, Buhl R, Laforce C, et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010;65:1086-91
   PubMed Web of Science ®Google Scholar
• van de Maele B, Fabbri LM, Martin C, et al. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. COPD 2010;7:418-27
   PubMedGoogle Scholar
• Westwood M, Bourbeau J, Jones PW, et al. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res 2011;12:40
   PubMed Web of Science ®Google Scholar
• Dahl R, Jadayel D, Alagappan VK, et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis 2013;8:501-8
   PubMed Web of Science ®Google Scholar
• Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484-94
   PubMed Web of Science ®Google Scholar
• Banerji D, Fogel R, Beeh KM. Dual bronchodilation for the treatment of chronic obstructive pulmonary disease: a review of the latest clinical data. Clin Invest 2014;4:511-33
   Google Scholar
• Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 2013;107:1558-67
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199-209
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013;1:51-60
   PubMed Web of Science ®Google Scholar
• Buhl R, Gessner C, Schuermann W, et al. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax 2015;70(4):311-19
   PubMedGoogle Scholar
• Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011;37:264-72
   PubMed Web of Science ®Google Scholar
• Dahl R, Gallagher N, Green Y, et al. QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD [abstract]. Eur Respir J 2013;42(Suppl 57):P3385
   Google Scholar
• Mahler DA, Decramer M, D’Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J 2014;43:1599-60
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55
   PubMed Web of Science ®Google Scholar
• Zhong N, Wang C, Zhou X, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study [abstract]. Eur Respir J 2014;44(Suppl 58):P2815
   Google Scholar
• Braido F, Baiardini I, Cazzola M, et al. Long-acting bronchodilators improve health related quality of life in patients with COPD. Respir Med 2013;107:1465-80
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Plaza V. Efficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: a systematic review. Chest 2014;146:309-17
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Brill SE, Allinson JP, et al. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med 2013;11:181
   PubMed Web of Science ®Google Scholar
• Banerji D, Fedele M, Chen H. Once-daily dual bronchodilation with QVA149 reduces COPD exacerbations: Results from the IGNITE program [abstract]. Chest 2014;145(3_MeetingAbstracts):403A
   Google Scholar
• Bateman E, Vogelmeier C, Chen H, et al. Comparison of COPD Exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study [abstract]. Chest 2014;145(3_MeetingAbstracts):409A
   Google Scholar
• Wedzicha JA, Decramer M, Seemungal TA. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J 2012;40:1545-54
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65
   PubMed Web of Science ®Google Scholar
• Wedzicha JA Decramer M, Olsson P, et al. QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: the SPARK study [abstract]. Eur Respir J 2014;44(Suppl 58):P898
   Google Scholar
• O’Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD 2007;4:225-36
   PubMedGoogle Scholar
• Beeh KM, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med 2014;108:584-92
   PubMed Web of Science ®Google Scholar
• Langer D, Ciavaglia CE, Neder JA, et al. Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment. Expert Rev Respir Med 2014;8:731-49
   PubMed Web of Science ®Google Scholar
• Mahler DA, O’Donnell DE. Recent advances in dyspnea. Chest 2015;147:232-41
   PubMed Web of Science ®Google Scholar
• Drollmann A, Brown M, Sechaud R, et al. Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers. Int J Clin Pharmacol Ther 2014;52:369-80
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Dahl R, Buhl R, et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med 2014;108:1498-507
   PubMed Web of Science ®Google Scholar
• Chapman KR, Fogarty CM, Peckitt C, et al. Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis 2011;6:353-63
   PubMed Web of Science ®Google Scholar
• Pavkov R, Mueller S, Fiebich K, et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin 2010;26:2527-33
   PubMed Web of Science ®Google Scholar
• Charles C. New options for optimal bronchodilation in chronic obstructive pulmonary disease. EMJ Respir 2014;2:58-66
   Google Scholar
• Dimke T, Kuttler A. A novel biophysical simulation model of drug deposition implemented to predict and optimize QVA149 delivery to the lungs [abstract]. Am J Respir Crit Care Med 2014;189:A3038
   Google Scholar
• European Medicines Agency. Ultibro Breezhaler. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002679/human_med_001691.jsp&mid=WC0b01ac058001d124 [Last accessed 7 January 2015]
   Google Scholar
• Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe 2014;10:110-20
   Google Scholar
• Pelaia G, Maselli R, Matera MG. Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium. Pharmacology 2014;94:249-58
   PubMed Web of Science ®Google Scholar
• Price D, Keininger D, Costa-Scharplatz M, et al. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respir Med 2014;108:1786-93
   PubMed Web of Science ®Google Scholar
• Cazzola M, Brusasco V, Centanni S, et al. Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists. Pulm Pharmacol Ther 2013;26:221-8
   Google Scholar
• D’Urzo A, Mahler DA, Olsson P, et al. Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: the BLAZE study [abstract]. Eur Respir J 2014;44(Suppl 58):P288
   Google Scholar
• Wedzicha JA, Decramer M, Vestbo J, et al. A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study [abstract]. Eur Respir J 2013;42(Suppl 57):P696
   Google Scholar
• Kraemer M, Ellis A, Baldwin M, et al. Dual bronchodilation with indacaterol and tiotropium in combination versus triple therapy, fixed-dose combinations, and monotherapy in COPD – a network meta-analysis of FEV1 [abstract]. Value Health 2012;15:A560
   Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371:1285-94
   PubMed Web of Science ®Google Scholar
• Vincken W, Aumann J, Goyal P, et al. Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: a post-hoc analysis from the GLOW6 study [abstract]. Eur Respir J 2014;44:P2410
   Google Scholar
• Frith P, Ratnavadivel R, Thompson P, et al. Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: the GLISTEN study [abstract]. Eur Respir J 2014;44(Suppl 58):P2811
   Google Scholar
• Cazzola M, Matera MG. Triple combinations in chronic obstructive pulmonary disease - is three better than two? Expert Opin Pharmacother 2014;15:2475-8
   PubMed Web of Science ®Google Scholar